Nanotechnology blooms, at last (Review)

Oncology Reports

Volumn 13, Issue 6, 2005, Pages 1003-1007

  Gordon, Erlinda M ^a,b   Hall, Frederick L ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Epeius Biotechnologies Inc   (United States)

Author keywords

Nanotechnology; Targeted delivery system

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; DRUG DELIVERY SYSTEM; HUMAN; NANOTECHNOLOGY; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; NEOPLASMS;

EID: 24744443165     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.6.1003     Document Type: Review

References (13)

1. Verma I and Somia N: Gene therapy: promises, problems and prospects. Nature 389: 239-242, 1997. (Pubitemid 27406627)
2. Peng KW and Russell SJ: Viral vector targeting. Curr Opin Biotechnol 10: 454-457, 1999.
3. Friedmann T: The road toward human gene therapy: a 25-year perspective. Ann Med 29: 575-577, 1997.
4. Gordon EM, Hall FL, Beart RW and Anderson WF: Genetic engineering of targeted retroviral vectors. In: Vector Targeting Strategies for Therapeutic Gene Delivery. Curiel DT and Douglas JT (eds). Wiley-Liss Inc., New York, NY, pp293-320, 2002.
5. Wu L, Yee A, Liu L, Carbonaro-Hall DA, Tolo VT and Hall FL: Molecular cloning of the human CYCG1 gene encoding a G-type cyclin: overexpression in human osteosarcoma cells. Oncol Rep 1: 705-711, 1994. (Pubitemid 2099327)
6. Pahre JN, Fuchs M, Levy J, Gordon EM and Hall FL: Molecular engineering of pathotropic vectors for cancer gene therapy. Bioproc J 3: 1-6, 2004.
7. Hall FL, Gordon EM, Wu L, et al: Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMuLV gp70 envelope protein. Hum Gene Ther 8: 2183-2192, 1997. (Pubitemid 28043556)
8. Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW and Gordon EM: Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 11: 983-993, 2000. (Pubitemid 30250115)
9. Gordon EM, Liu PX, Zhen ZH, et al: Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res 60: 3343-3347, 2000. (Pubitemid 30482143)
10. Gordon EM, Liu PX, Chen ZH, et al : Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 12: 193-204, 2001. (Pubitemid 32095457)
11. Miller DG, Adam MA and Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239-4242, 1990.
12. Lenz HJ, Anderson WF, Hall FL and Gordon EM: Tumor site-specific phase I evaluation of safety of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to the liver. Hum Gene Ther 13: 1515-1537, 2002.
13. Gordon EM, Cornelio GH, Lorenzo CC, Levy JP, Reed RA, Liu L and Hall. FL: First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol 24: 177-185, 2004.